<DOC>
	<DOC>NCT02110992</DOC>
	<brief_summary>The purpose of this research study is to test the safety of a chemotherapy drug called docetaxel and focused radiation therapy (SBRT) and see what effects (good and bad) it has on recurrent head and neck cancer that is not surgically removable.</brief_summary>
	<brief_title>Safety Study of SBRT and Docetaxel for Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Head and Neck</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Recurrent or second primary squamous cell head and neck cancer Defined area of recurrence on imaging Previous head and neck radiation (RT) to &gt;/= 50 Gy Performance status score 01 Time interval from previous RT &gt;/= 9 months Volume of disease appropriate for protocol treatment Minimum estimated survival of &gt;/= 3 months Age &gt;/= 18 Adequate labs Primary tumors of the salivary gland Original pathology report and radiation therapy records not available Prior spinal cord dose &gt; 45 Gy Surgery or chemotherapy within 4 weeks Prior invasive malignancy (except nonmelanomatous skin cancer) unless disease free for a minimum of 3 years; noninvasive cancers are permitted</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>